Polypeptide capable of directionally enhancing killing effect of thymic neogenesis T cells on breast cancer and application of polypeptide

By designing a polypeptide assembled by Th cells and B cell epitope sequences, the killing function of thymus new T cells on breast cancer is enhanced, and the problems of large side effects of existing breast cancer treatment methods and insufficient therapeutic effectiveness are achieved. Effective inhibition and treatment effects of breast cancer are improved.

CN119019569AActive Publication Date: 2024-11-26ARMY MEDICAL UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411137697.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-26
Estimated Expiration
2044-08-19

AI Technical Summary

Technical Problem

The existing breast cancer treatment methods have problems such as large side effects, insufficient treatment accuracy and effectiveness, especially the complex physiological structure of the tumor site and abnormal blood vessels, which makes it difficult for the drug to penetrate effectively, affecting the treatment effect.

Method used

A polypeptide was designed to assemble Th cell epitope sequence, tetra residue linker and B cell epitope sequence, and prepared by Fmoc solid phase synthesis method to enhance the killing function of thymic neogenesis T cells on breast cancer. Specifically The sequence is KLLSLIKGVIVHRLEGVE-GPSL-KDMQLGR, which can inhibit breast cancer tumor growth and enhance T cell function.

Benefits of technology

This polypeptide can effectively inhibit the growth of breast cancer tumors, enhance the killing function of thymus T cells, and reduce toxic side effects. It provides a new breast cancer treatment plan and improves the accuracy and effectiveness of the treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019569A_ABST
    Figure CN119019569A_ABST
Patent Text Reader

Abstract

The invention discloses a polypeptide capable of directionally enhancing the killing effect of thymic neogenesis T cells on breast cancer and application of the polypeptide. The sequence of a peptide fragment is NH2-KLLSLIKGVIVHRLEGVE-GPSL-KDMQLGR-CONH2. The invention further discloses a preparation method of the polypeptide. A Th cell epitope sequence (KLLSLIKGVIVHRLEGVE) is from a measles virus fusion protein 288-302 peptide fragment (MVF), and a four-residue connector (GPSL) is arranged behind a T cell epitope. The linker is integrated into the fusion peptide to aid in independent folding of the T cell epitope and the B cell epitope. And the B cell epitope sequence is a C segment of C5a (KDMQLGR). The polypeptide can inhibit breast cancer tumor growth, enhance thymus T cell function output and enhance the directional killing function of T cells on breast cancer, reduces toxic and side effects, can be applied to breast cancer treatment, and provides a new scheme and a new idea for breast cancer treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine, and provides a polypeptide capable of directionally enhancing thymus-derived T cells from killing breast cancer and its application. Background Art

[0002] Breast cancer is a common malignant tumor in women worldwide, and its incidence rate continues to rise, seriously threatening women's lives and health. Existing treatments for breast cancer include surgical treatment, radiotherapy, chemotherapy, etc. However, these treatments have defects and shortcomings. For example, surgery can only remove cancer cells that have formed solid lesions, and cannot completely remove cancer cells, while radiotherapy and chemotherapy have large side effects, including hair loss, nausea, fatigue, immune system suppression, etc. These side effects affect the quality of life of patients. In addition, the physiological structure of the tumor site is complex, and the local drug concentration is often difficult to reach the ideal level. Abnormal tumor blood vessels also lead to increased interstitial pressure and blood flow stagnation, making it difficult for drugs to effectively penetrate into tumor tissues, affecting the overall treatment effect. Therefore, it is urgent to develop new treatment methods to overcome the defects of existing methods, improve the accuracy and effectiveness of treatment, reduce side effects, and ultimately achieve the goal of improving the survival rate and quality of life of breast cancer patients. In recent years, immunotherapy has made significant progress in the field of treating malignant tumors, providing a new option for breast cancer treatment.

[0003] Studies have shown that B cell epitope peptides targeting C5a can effectively alleviate the symptoms of Alzheimer's disease by activating plasma cells to produce specific antibodies against C5a and reducing the interaction between C5a and C5aR, but its anti-tumor biological activity in vivo has not been reported. Complement C5a binds to its receptor C5aR and can promote the development of breast cancer. Therefore, targeting C5a / C5aR may be an effective strategy for tumor immunotherapy.

[0004] At present, there is no relevant report on the polypeptide of the present invention. Summary of the invention

[0005] In view of this, the purpose of the present invention is to provide a polypeptide that can directionally enhance the killing of breast cancer by thymic newly generated T cells and its application, so as to achieve immunotherapy for breast cancer.

[0006] To achieve the above object, the present invention provides the following technical solutions:

[0007] 1. A polypeptide that can enhance the killing of breast cancer by thymic newly born T cells is obtained by sequentially connecting and assembling the following peptide segments:

[0008] (1) Th cell epitope sequence: KLLSLIKGVIVHRLEGVE;

[0009] (2) Four-residue linker: GPSL;

[0010] (3) B cell epitope sequence: KDMQLGR.

[0011] As one of the preferred technical solutions, the assembled peptide sequence is:

[0012] KLLSLIKGVIVHRLEGVEGPSLKDMQLGR, as shown in SEQ ID NO.1.

[0013] 2. The preparation method of the aforementioned polypeptide capable of directionally enhancing thymic newly born T cells to kill breast cancer is obtained by connecting and assembling according to the following amino acid sequence: KLLSLIKGVIVHRLEGVEGPSLKDMQLGR, as shown in SEQ ID NO.1.

[0014] As one of the preferred technical solutions, the Fmoc solid phase synthesis method is used to connect and assemble according to the amino acid sequence shown in SEQ ID NO.1.

[0015] As one of the further preferred technical solutions, the Fmoc solid phase synthesis method is used to connect the first amino acid at the C-terminus of the polypeptide to the PS resin support, and then the amino acids are condensed in sequence from the C-terminus to the N-terminus according to the sequence of the polypeptide; the amino acid is protected by the Fmoc (9-fluorenylmethoxycarbonyl) group at its amino terminus, and after activation at the carboxylic acid terminus, it is coupled with the growing chain (a polypeptide chain gradually constructed on the resin support; amino acid residues are gradually added from the C-terminus (carboxyl terminus) to the N-terminus (amino terminus) until the expected sequence length is reached); the Fmoc group is then removed by piperidine treatment and the process is repeated to complete the peptide assembly.

[0016] As one of the further preferred technical solutions, after the peptide is assembled, it can be removed from the resin support by treating it with trifluoroacetic acid (TFA); at the same time, the protecting groups on the amino acid side chains are also removed to obtain a crude linear peptide; the polypeptide is purified by high performance liquid chromatography (HPLC) to remove by-products and unreacted substances.

[0017] HPLC chromatographic conditions:

[0018] Chromatographic column: kromasil C18-5 column (4.6*150mm); mobile phase A is 0.1% trifluoroacetic acid acetonitrile solution by volume, B is 0.1% trifluoroacetic acid aqueous solution by volume, gradient elution (at 0.01min, 5% A95%B, at 25.0min, 75%A25%B, at 30min, 90%A 10%B; changes in mobile phase all refer to volume percentage); flow rate 1.0mL / min; detection wavelength 214nm; injection volume 20ul.

[0019] MS mass spectrometry conditions: expected MS is 3185.88; flow rate is 0.2 mL / min; running time is 1 min; buffer A is a 0.1% by volume formic acid aqueous solution, and buffer B is a 0.1% by volume formic acid acetonitrile solution.

[0020] 3. Use of the aforementioned polypeptide that can directionally enhance thymic newly born T cells to kill breast cancer in the preparation of anti-breast cancer drugs.

[0021] The beneficial effects of the present invention are:

[0022] The present invention prepares a polypeptide that can enhance the killing of breast cancer by thymic newborn T cells, and the peptide sequence is NH 2 -KLLSLIKGVIVHRLEGVE-GPSL-KDMQLGR-CONH 2 The Th cell epitope sequence (KLLSLIKGVIVHRLEGVE) is derived from the 288-302 peptide segment of the measles virus fusion protein (MVF), and the T cell epitope is followed by a four-residue linker (GPSL). The linker is incorporated into the fusion peptide to aid in the independent folding of the T cell epitope and the B cell epitope. The B cell epitope sequence is the C segment of C5a (KDMQLGR).

[0023] The polypeptide of the present invention can inhibit the growth of breast cancer tumors, enhance the functional output of thymic T cells and enhance the directional killing function of T cells against breast cancer, reduce toxic side effects, and can be applied to the treatment of breast cancer, providing new solutions and new ideas for the treatment of breast cancer.

[0024] Other advantages, objectives and features of the present invention will be described in the following description to some extent, and to some extent, will be obvious to those skilled in the art based on the following examination and study, or can be taught from the practice of the present invention. The objectives and other advantages of the present invention can be realized and obtained through the following description. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention will be described in detail below in conjunction with the accompanying drawings, wherein:

[0026] Figure 1 This is the result of Max449 peptide HPLC analysis;

[0027] Figure 2 This is the result of Max449 peptide MS analysis;

[0028] Figure 3 This is the result of the anti-breast cancer peptide acting on the in vitro transplanted tumor model of Balbc mice;

[0029] Figure 4The tumor volume of the in vitro transplanted tumor model of Balbc mice was measured by the anti-breast cancer peptide.

[0030] Figure 5 The tumor weight of the in vitro transplanted tumor model of Balbc mice was measured by the action of anti-breast cancer peptides.

[0031] Figure 6 The changes of newly born T cells in the thymus of the Balbc mouse in vitro transplanted tumor model induced by anti-breast cancer peptides. DETAILED DESCRIPTION

[0032] The present invention will be further described below in conjunction with specific implementation modes.

[0033] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0034] Embodiment 1:

[0035] Preparation of anti-breast cancer peptide (Max449 peptide)

[0036] The sequence of the anti-breast cancer peptide is NH 2 -KLLSLIKGVIVHRLEGVE-GPSL-KDMQLGR-CONH 2 The Th cell epitope sequence (KLLSLIKGVIVHRLEGVE) is derived from the 288-302 peptide segment of the measles virus fusion protein (MVF), and the T cell epitope is followed by a four-residue linker (GPSL). The linker is incorporated into the fusion peptide to aid in the independent folding of the T cell epitope and the B cell epitope. The B cell epitope sequence is a C segment fragment of C5a (KDMQLGR)

[0037] Preparation method: It is assembled by sequentially connecting the following peptide segments: (1) Th cell epitope sequence:

[0038] KLLSLIKGVIVHRLEGVE; (2) Four-residue linker: GPSL; (3) B cell epitope sequence: KDMQLGR.

[0039] Using the Fmoc solid phase synthesis method, the first amino acid at the C-terminus of the peptide is connected to the PS resin support, and then the amino acids are condensed in order from the C-terminus to the N-terminus according to the sequence of the peptide; the amino acid is protected by the Fmoc (9-fluorenylmethoxycarbonyl) group at its amino terminus and coupled to the growing chain after activation of the carboxylic acid terminus; the Fmoc group is then removed by piperidine treatment and the process is repeated to complete the peptide assembly. After the peptide is assembled, it can be removed from the resin by treatment with trifluoroacetic acid (TFA); at the same time, the protecting groups on the amino acid side chains are also removed to obtain a crude linear peptide; the peptide is purified by high performance liquid chromatography (HPLC) to remove by-products and unreacted substances (such as Figure 1 shown).

[0040] HPLC chromatographic conditions:

[0041] Chromatographic column: kromasil C18-5 column (4.6*150mm); mobile phase A is 0.1% trifluoroacetic acid acetonitrile solution by volume, B is 0.1% trifluoroacetic acid aqueous solution by volume, gradient elution (0.01min, 5% A 95% B, 25.0min, 75% A 25% B, 30min, 90% A 10% B; changes in mobile phase all refer to volume percentage); flow rate 1.0mL / min; detection wavelength 214nm; injection volume 20ul.

[0042] Structural identification: Mass spectrometry (MS) is used to determine the molecular weight and composition of the peptide (e.g. Figure 2 As shown), MS mass spectrometry conditions: expected MS is 3185.88; flow rate is 0.2 mL / min; running time is 1 min; buffer A is a 0.1% by volume formic acid aqueous solution, and buffer B is a 0.1% by volume formic acid acetonitrile solution.

[0043] Embodiment 2:

[0044] In vivo peptide therapy test in mice

[0045] 4T-1 cells (Wuhan Punosai Life Science Co., Ltd.) were injected subcutaneously in the right axilla of 6- to 8-week-old female Balbc mice (Chongqing Tengxin Bill Experimental Animal Sales Co., Ltd.) (3*10 5 100 μL) 4 to 6 days after tumor formation, the length and width of the tumor were measured every 2 days using a vernier caliper. Tumor volume was calculated as length × width 2 / 2(mm 3The mice were randomly divided into three treatment groups (5 mice in each group): PBS treatment group (Ctrl), anti-tumor peptide (SEQ ID NO: 7, patent CN103269711B) treatment group and anti-tumor peptide (Max449) treatment group. On the second day after tumor bearing, mice were injected with 1 mg / ml peptide (control group was injected with PBS), and the drug was administered every other day for a total of four times. The weight and volume of the tumor were measured 17 days after treatment, and flow cytometry analysis (FACSymphony TM A1, BD Biosciences) detects CD8 + Changes in T cells, such as Figures 3 to 6 shown.

[0046] Figure 3 4T-1 cells (3*10 5 100 μL) (n=5 per group), group 1 was treated with PBS, group 2 was treated with anti-tumor polypeptide (SEQ ID NO: 7, patent CN103269711B), group 3 was treated with anti-tumor polypeptide (Max449), mice were injected with 1 mg / ml polypeptide (control group was injected with PBS), and the drugs were administered every other day for a total of four times. The tumors were harvested 17 days after treatment.

[0047] Figure 4 4T-1 cells (3*10 5 100 μL) (n=5 per group), group 1 was treated with PBS, group 2 was treated with anti-tumor polypeptide (SEQ ID NO: 7, patent CN103269711B), group 3 was treated with anti-tumor polypeptide (Max449), mice were injected with 1 mg / ml polypeptide (control group was injected with PBS), and the drugs were administered every other day for a total of four times. After 17 days of treatment, the tumors were harvested, and the length and width of the tumors were measured with a caliper. The tumor volume was calculated as length × width 2 / 2(mm 3 )(n=5 per group).

[0048] Figure 5 4T-1 cells (3*10 5 100 μL) (n=5 per group), group 1 was treated with PBS, group 2 was treated with anti-tumor polypeptide (SEQ ID NO: 7, patent CN103269711B), group 3 was treated with anti-tumor polypeptide (Max449), mice were injected with 1 mg / ml polypeptide (control group was injected with PBS), and the drugs were administered every other day for a total of four times. After 17 days of treatment, the tumors were weighed.

[0049] Figure 64T-1 cells (3*10 5 100 μL) (n=3 per group), group 1 was treated with PBS, group 2 was treated with anti-tumor peptide (SEQ ID NO: 7, patent CN103269711B), group 3 was treated with anti-tumor peptide (Max449), mice were injected with 1 mg / ml peptide (control group was injected with PBS), and the drug was administered every other day for a total of four times. Tumors were harvested 17 days after treatment, and CD8 + Changes in T cells.

[0050] Compared with the Ctrl group and the anti-tumor polypeptide (SEQ ID NO: 7, patent CN103269711B) group, the tumor volume and weight of the anti-tumor polypeptide Max449 group were smaller, indicating that the anti-tumor polypeptide Max449 can significantly inhibit tumor growth. + The increase in T cells indicates an increase in newly generated T cells in the thymus. The above experiments show that the anti-tumor peptide Max449 can effectively treat breast cancer.

[0051] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution, which should be included in the scope of the claims of the present invention.

Claims

1. A polypeptide that can enhance the killing of breast cancer by thymic newly born T cells, characterized in that: It is assembled by connecting the following peptide segments in sequence: (1) Th cell epitope sequence: KLLSLIKGVIVHRLEGVE; (2) Four-residue linker: GPSL; (3) B cell epitope sequence: KDMQLGR.

2. A method for preparing a polypeptide capable of directionally enhancing thymic newly generated T cells to kill breast cancer as claimed in claim 1, characterized in that: The amino acid sequence is connected and assembled in sequence as follows: KLLSLIKGVIVHRLEGVEGPSLKDMQLGR, as shown in SEQ ID NO.

1.

3. The preparation method according to claim 2, characterized in that: The Fmoc solid phase synthesis method was used to connect and assemble according to the amino acid sequence shown in SEQ ID NO.

1.

4. The preparation method according to claim 3, characterized in that: Using the Fmoc solid-phase synthesis method, the first amino acid at the C-terminus of the peptide is connected to the PS resin support, and then the amino acids are condensed in order from the C-terminus to the N-terminus according to the sequence of the peptide; the amino acids are protected by the Fmoc group at their amino termini and coupled to the growing chain after activation of the carboxylic acid termini; the Fmoc group is then removed by piperidine treatment and the process is repeated to complete the peptide assembly.

5. The preparation method according to claim 4, characterized in that: After the peptide is assembled, it is removed from the resin by treating it with trifluoroacetic acid; at the same time, the protecting groups on the amino acid side chains are also removed to obtain a crude linear peptide; the peptide is purified by high-performance liquid chromatography to remove by-products and unreacted substances.

6. Use of the polypeptide capable of directionally enhancing thymic newly born T cells to kill breast cancer as claimed in claim 1 in the preparation of anti-breast cancer drugs.

Citation Information

Patent Citations

  • Vaccines based on peptides of complement protein c5a

    CN103269711B

  • Vaccines based on peptides of the complement protein C5a

    CN103269711A

  • Human PD1 peptide vaccines and uses thereof

    CN110636855A

  • Her-2 peptides

    US20070060516A1